Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF")
Regulatory News: ADOCIA (Euronext Paris: FR0011184241 ADOC), a clinical-stage biopharmaceutical company specialized in the development of innovative formulations of proteins and peptides, announces
ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC the
company) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, confirms that it will hold its Annual General Meeting ( AGM ) on May 20, 2021 at 10:00 a.m., at Adocia s offices, 115 avenue Lacassagne, 69003, Lyon, France.
The Shareholders Meeting will also be broadcast live on the Company s website (www.adocia.com under Investors Shareholder Meeting ) by audio webcast via conference call without possibility to interact.
The video will be available on a deferred basis within the timeframe provided for by the regulations.
Number of Shares and Voting Rights of ADOCIA as of February 28th, 2021
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (
Autorité des Marchés Financiers, or AMF ) charter ADOCIA SA (Paris:ADOC), a French
société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of February 28th, 2021.
Month
9 773 093
(1) The total number of theoretical voting rights (or gross voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including sh
Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
1c
The study has been designed to define parameters for the upcoming Phase 3 trial planned for 2022
This study follows the promising results of the proof-of-concept Phase 1 trial announced on September 15, 2020
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases, announced today the initiation of a Phase 2 study in type 1 diabetes (T1D). The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog